Vinnie, Vin Milano became the CEO of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) in 2014. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we will consider the growth in the business. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This method should give us information to assess how appropriately the company pays the CEO.

Check out our latest analysis for Idera Pharmaceuticals

How Does Vinnie, Vin Milano's Compensation Compare With Similar Sized Companies?

According to our data, Idera Pharmaceuticals, Inc. has a market capitalization of US$55m, and paid its CEO total annual compensation worth US$1.8m over the year to December 2018. While this analysis focuses on total compensation, it's worth noting the salary is lower, valued at US$600k. We further remind readers that the CEO may face performance requirements to receive the non-salary part of the total compensation. We looked at a group of companies with market capitalizations under US$200m, and the median CEO total compensation was US$523k.

As you can see, Vinnie, Vin Milano is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Idera Pharmaceuticals, Inc. is paying too much. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.

You can see a visual representation of the CEO compensation at Idera Pharmaceuticals, below.

Is Idera Pharmaceuticals, Inc. Growing?

Over the last three years Idera Pharmaceuticals, Inc. has grown its earnings per share (EPS) by an average of 17% per year (using a line of best fit). Its revenue is up 110% over last year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's great to see that revenue growth is strong, too. These metrics suggest the business is growing strongly. Shareholders might be interested in this free visualization of analyst forecasts.

Has Idera Pharmaceuticals, Inc. Been A Good Investment?

With a three year total loss of 85%, Idera Pharmaceuticals, Inc. would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.

In Summary...

We compared the total CEO remuneration paid by Idera Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies. As discussed above, we discovered that the company pays more than the median of that group.